Akcea Therapeutics Inc
AKCA
AKCA was delisted on the 9th of October, 2020.
62 hedge funds and large institutions have $704M invested in Akcea Therapeutics Inc in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 14 closing their positions.
62% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $8.11M
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
5% less funds holding
Funds holding: 65 → 62 (-3)
14% less capital invested
Capital invested by funds: $817M → $704M (-$113M)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.27M |
| 3 |
BlackRock
New York
|
+$3.19M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$2.09M |
| 5 |
MFAM
Motley Fool Asset Management
Alexandria,
Virginia
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$18.4M |
| 2 |
AA
ALPS Advisors
Denver,
Colorado
|
-$5.31M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.23M |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$1.93M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.06M |
AKCA Hedge Fund Activity: Q4 2018 in Review
62 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q4 2018, worth a combined $704M — down 14% from $817M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AKCA and 11 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 22 added.
The largest buyer was Fidelity Investments, adding an estimated $14.7M. The largest seller was Wellington Management Group, cutting an estimated $18.4M.
- 62 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q4 2018, down from 65 in Q3 2018.
- Funds reported $704M of Akcea Therapeutics Inc stock for Q4 2018, down 14% quarter-over-quarter.
- 11 funds opened new Akcea Therapeutics Inc positions in Q4 2018 and 14 closed out, a net change of -3 holders.
- The largest Akcea Therapeutics Inc buyer in Q4 2018 was Fidelity Investments, an estimated $14.7M added.
- The largest Akcea Therapeutics Inc seller in Q4 2018 was Wellington Management Group, an estimated $18.4M sold.
Based on aggregated 13F filings for Q4 2018.